SEC filing record
Primary Source · SEC.gov

BTB Therapeutics, Inc.

2025 vintageRule 506(b)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalSold increasedForm D/A · 2026-08-124 events: 2 new form d filer, 1 sold increased, 1 offering upsizedLast filing 2026-08-12

Raised

$9M

Investors

4

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

BTB Therapeutics, Inc. is a Delaware corporation that first filed a Form D on February 5, 2025 and most recently amended it on August 12, 2026 in the Pharmaceuticals industry group. The offering claims Rule 506(b) and covers equity. BTB Therapeutics, Inc. reported $8,902,204 sold from 4 investors of a $10,402,704 total offering as of the Form D filed August 12, 2026. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. The issuer's address of record is 26281 Wyndemere Court, Escondido, CA 92026.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0002055053
Entity NameBTB Therapeutics, Inc.
ExemptionRule 506(b)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising.
Entity TypeCorporation
Jurisdiction of OrganizationDelaware
Issuer Address26281 Wyndemere Court, Escondido, CA 92026
Phone(858) 945-3733
Industry / Fund TypePharmaceuticals
Securities TypeEquity
First Sale DateNovember 14, 2025
Filing DateAugust 12, 2026
Accession Number0002055053-26-000003
Total Offering Amount$10,402,704
Total Amount Sold$8,902,204
Amount Remaining$1,500,500
Total Investors4
Non-Accredited InvestorsNone
Minimum Investment$0 (no stated minimum)
Offering DurationOne year or less
Revenue RangeDecline to Disclose
State (Issuer Address)CA
Amendment Count3 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

4

latest Aug 12, 2026

Critical / warning

0 / 0

1 watch · 3 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

2

lapsed, raising

Latest event Sold increase · Aug 12, 2026

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 4 filing events with values and deltas, latest 2026-08-12, and alerts on the next one
  • 2 offering timelines: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Item 3 changed on the Form D filed 2026-08-12: 1 related person added and 0 removed against the filing of 2025-12-01; 5 now listed. The names are in the Terminal feed.

Takashi Kiyoizumi

Executive Officer, Director · Escondido, CA

Nobuhiro Yagi

Director · Escondido, CA

Masatoshi Hagiwara

Director · Escondido, CA

David Snyder

Director · Escondido, CA

Sidney Yee

Director · Escondido, CA

Questions About BTB Therapeutics, Inc.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is BTB Therapeutics, Inc.?

BTB Therapeutics, Inc. is a Delaware corporation that filed a Form D with the SEC on August 12, 2026 in the Pharmaceuticals industry group. The filing claims Rule 506(b) for an offering of equity.

Is BTB Therapeutics, Inc. legit?

AltStreet does not rate legitimacy; it reports the public record. BTB Therapeutics, Inc. filed a Form D with the SEC on August 12, 2026 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $8,902,204 sold to 4 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is BTB Therapeutics, Inc. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that BTB Therapeutics, Inc. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has BTB Therapeutics, Inc. raised?

BTB Therapeutics, Inc. reported $8,902,204 sold from 4 investors of a $10,402,704 total offering as of the Form D filed August 12, 2026.

Who can invest in BTB Therapeutics, Inc.?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.

What is the minimum investment in BTB Therapeutics, Inc.?

The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.

Who is selling BTB Therapeutics, Inc. and how are they paid?

The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly.

Who is behind BTB Therapeutics, Inc.?

The Form D lists 5 related persons: Takashi Kiyoizumi, executive officer, director; Nobuhiro Yagi, director; Masatoshi Hagiwara, director; David Snyder, director; Sidney Yee, director. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is BTB Therapeutics, Inc. located?

The issuer's address on its SEC filings is 26281 Wyndemere Court, Escondido, CA 92026. Its phone number of record is (858) 945-3733. It is organized under the laws of Delaware.

How long is the BTB Therapeutics, Inc. offering open?

The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 1 amendment is on record for this CIK.

What is BTB Therapeutics, Inc.'s revenue?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.